Metal Ion Nucleic Acid Aptamer Screening Service Workflow Step Service Content Timeline Step 1: Screening of nucleic acid aptamers (1) Customer provides screening targets. (2) The adapter library is fixed on an affinity chromatography column and incubated with metal ions injected into the column. (3) Adaptation library screening and enrichment: PCR amplification enrichment+transcription+gel running recovery, usually 6-10 rounds. (4) Screening products for NGS sequencing. (5) Delivery: 5-15 adapter sequences, experimental report, raw data (including NGS sequencing raw data and gel electrophoresis) 10-15 weeks Step2：Synthesis of aptamers and determination of affinity (optional) (1) Synthesize aptamers based on sequences. (2) Affinity determination of adapter and target protein, KD determination by BLI or SPR. (3) Delivery: Experimental report, raw data
KMD Bioscience, with years of research experience in antibody discovery, focuses on providing customers with efficient, highly specific, and affinity nucleic acid aptamer in vitro screening services. Based on customers' specific screening targets, we tailor aptamer selex screening solutions and quickly and accurately screen aptamers for the target. KMD Bioscience can provide aptamer selex screening services based on multiple sample types (including proteins, peptides, amino acids, small molecule substances, cells and bacteria, metal ions, etc.), and the services provided to customers cover the upstream and downstream of aptamer selex screening, from gene analysis and synthesis, nucleic acid aptamer sequence design, aptamer in vitro screening, aptamer synthesis, to affinity determination. KMD Bioscience can arrange experiments at every stage according to customer needs. For some metal ions with simple structures and single binding sites, KMD Bioscience uses affinity chromatography SELEX and graphene oxide SELEX screening techniques, carefully planned by a team of scientists to meet the diverse needs of customers. The nucleic acid aptamer services provided by KMD Bioscience for various types of samples are based on the SELEX screening technology of the SELEX library to screen and obtain corresponding DNA or RNA sequences. Multiple screening methods (including but not limited to cell-SELEX, magnetic bead SELEX, affinity chromatography SELEX, capture SELEX,…
1. What is the cell aptamer screening service, and what are the advantages of cell aptamers? A: Our common aptamers include RNA aptamers and DNA aptamers, which targets have high affinity and specificity and are capable of high binding to the target. These aptamers have multiple functions in disease treatment and scientific research. First, it acts as a cell agonist to activate cell receptors and promote the cell to exert its effects. Secondly, it has the effect of antagonist to block the mutual binding and interaction between various structures. Furthermore, the aptamer can bind to the target so that the drug can be accurately transmitted to the therapeutic target. During the cell-SELEX screening, intact live cells were screened as a target, while the associated cell lines were used as negative controls for negative screening to exclude non-specific binding. The Cell-SELEX technology targets multiple cellular targets to generate nucleic acid aptamers, thus providing an advantage in identifying cells as molecules. In disease diagnosis, we can use aptamers for labeling, or use aptamers as a fixative to depurify the cells. These properties of aptamers provide new ideas for novel drug development. One of the highlights of the Cell-SELEX technology is the ability to retain the original conformation of the cellular receptor, which is different from screening…
Steps Service Content Timeline Step 1: Screening of nucleic acid aptamers (1) Cells were provided by the customer. (2) Adaptation library screening and enrichment: PCR amplification enrichment+transcription+gel running recovery, usually 6-10 rounds. (3) Screening products for NGS sequencing. (4) Delivery: 5-15 adapter sequences, experimental report, raw data (including NGS sequencing raw data and gel electrophoresis) 10-15 weeks Step2：Aptamer assay and FACS(optional) (1) Synthesize aptamers based on sequences. (2) Affinity determination of adapter and FACS. (3) Delivery: Experimental report, raw data 4-5 weeks
The specific screening process and sample requirements will vary according to the target characteristics and experimental requirements. The process of cell targeting aptamers screening is mainly based on SELEX technology and optimized using the aptamer cell selex method to meet the screening needs at the cellular level. A aptamer library containing a large number of random nucleic acid sequences (DNA or RNA, typically between 20 and 60 nucleotides in length) is constructed. Specific molecules on target cells or cell surfaces are used as targets (cell culture, purification, or labeling). The target cells are mixed with nucleic acid sequences from the aptamer library, and after incubation, the nucleic acid sequences bind to molecules on the surface of the target cells. The nucleic acid sequence that binds to the target is separated through filtration, centrifugation, magnetic bead separation, and other methods. The combined nucleic acid sequence is eluted and collected for the next round of screening. The secondary library is generated by amplifying the eluted nucleic acid sequence using PCR technology. The steps of binding, separation, elution, and amplification are repeated to gradually enrich high affinity aptamers. Through sequencing and sequence analysis, candidate aptamers were identified from the final enriched library. Simply put, SELEX…
As a functional nucleic acid, aptamer has many advantages. Based on its high specificity, it can accurately find the target molecule, thus avoiding the interference caused by nonspecific binding. Through in vitro selection technology (SELEX) screening, aptamers can be synthesized rapidly and in large quantities without complex biological preparation process. Aptamers have good chemical stability, can keep their structure and function unaffected under a variety of environmental conditions, and have higher thermal stability and lower immunogenicity. The molecular weight of aptamers is relatively small, making it easier for them to penetrate cell and tissue barriers and reach the site of action quickly. The core of aptamer screening is SELEX technology, which can accurately screen nucleic acid molecules that can achieve highly specific binding with specific targets from a large number of nucleic acid libraries with diverse sequences after multiple rounds of selection and amplification cycles. DNA or RNA aptamers obtained by in vitro screening technology have a unique three-dimensional structure, which can accurately identify and tightly bind to the corresponding target molecules. Compared with traditional antibodies, aptamers exhibit a variety of advantages, such as thermal stability, chemical synthesis and modification ability, and low immunogenicity. These characteristics together determine the great…
KMD Bioscience has many years of research experience in the field of drug antibodies, and has accumulated profound experience in antibody development, aptamer screening, aptamer assay, affinity maturation, etc. KMD Bioscience can provide aptamer screening services for a variety of sample types, such as proteins, peptides, amino acids, small molecular substances, cells and bacteria, metal ions, etc. KMD Bioscience can provide customized in vitro aptamer screening services to ensure efficient, accurate and rapid screening of aptamer sequences required by customers. In addition, KMD Bioscience can provide customers with upstream and downstream services covering aptamer screening, from gene analysis and synthesis, aptamer in vitro screening, aptamer synthesis, aptamer assay, to affinity determination. KMD Bioscience can provide strong support for subsequent functional verification of aptamers (including but not limited to affinity verification, competitive ELISA verification, in vitro targeted cell functional verification (such as in vitro recognition and inhibition function verification of nucleic acid aptamers, in vitro flow cytometry blocking function verification, etc.), and in vivo functional verification (such as in vivo targeted inhibition function verification of aptamers, signal pathway blocking function verification, etc.), laying a solid foundation for subsequent work of customers, such as downstream research and development of targeted specific molecular drugs. The nucleic acid aptamer screening service based on SELEX technology provided…
Nucleic Acid Aptamer Synthesis Service Advantages ✔ The library has a capacity of 10 ^ 13-10 ^ 14, sufficient to screen for nucleic acid aptamers targeting customer targets. ✔ SELEX technology platform mature: the affinity of nucleic acid aptamers obtained through screening can reach the nM-pM level. ✔ Traceability of experimental records: QC quality control standards, Chinese and English experimental reports, original experimental records. ✔ One on one personalized solution customization (including screening and subsequent verification plans, etc.) to meet the research project needs of various clients. ✔6-10 rounds of pressure screening can obtain high affinity and high specificity nucleic acid aptamers.
Nucleic acid aptamers exhibit exceptional specificity in recognizing and binding to their target molecules, allowing them to pinpoint targets amidst a myriad of molecules, effectively sidestepping the disruptions posed by nonspecific binding. Their binding capacity with target molecules is robust, sometimes even surpassing that of antibodies. This superior affinity renders nucleic acid aptamers exceptionally sensitive and precise in applications like detection and diagnosis. SELEX technology offers a highly efficient and targeted approach for the screening of nucleic acid aptamers, thereby advancing their utilization and progress across diverse domains. KMD Bioscience employs this SELEX technology to identify aptamers with strong affinity for specific, targeted substances from a randomly generated library of single-stranded nucleic acid aptamers. KMD Bioscience uses advanced SELEX screening technology to accurately extract oligonucleotides with high affinity for targets from a large random library. After multiple rounds of screening cycles, SELEX fragments were sequenced based on their enrichment levels to obtain adapter sequences (RNA aptamers, DNA aptamers). Among them, the oligonucleotide library has been uniquely designed with fixed sequences at both ends and cleverly inserted with random sequences (RNA aptamers, DNA aptamers) in the middle. In the fixed sequence section, primer binding sites that are conducive to PCR amplification…
